Clinical trial • Phase II/III • Cardiology

DANICAMTIV for Dilated cardiomyopathy | Genetic dilated cardiomyopathy | Familial dilated cardiomyopathy

Phase II/III trial of DANICAMTIV for Dilated cardiomyopathy | Genetic dilated cardiomyopathy | Familial dilated cardiomyopathy.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Dilated cardiomyopathy | Genetic dilated cardiomyopathy | Familial dilated cardiomyopathy
Trial Stage
Phase II/III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
30-09-2025
First CTIS Authorization Date
30-01-2026

Trial design

Randomised, placebo tablets containing the same excipients as danicamtiv tablets (placebo arm). dose and schedule not specified in the provided documents.-controlled, adaptive Phase II/III trial in Italy, Netherlands, Hungary and others.

Randomised
Yes
Comparator
Placebo tablets containing the same excipients as Danicamtiv tablets (placebo arm). Dose and schedule not specified in the provided documents.
Adaptive
True, study described as adaptive (Phase 2b/3). Specific adaptive elements (interim analyses, stopping rules, or detailed adaptation rules) are not provided in the available materials.
Target Sample Size
92
Trial Duration For Participant
182

Eligibility

Recruits 92 Vulnerable population selected (isVulnerablePopulationSelected = true). All participants must be adults (≥18 years). Written informed consent must be provided by the participant according to local and institutional guidelines before the first study-specific procedure. No assent or parental consent provisions are described in the provided material..

Pregnancy Exclusion
30. Is pregnant or breastfeeding.
Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected = true). All participants must be adults (≥18 years). Written informed consent must be provided by the participant according to local and institutional guidelines before the first study-specific procedure. No assent or parental consent provisions are described in the provided material.

Inclusion criteria

  • {"criterion_text":"- 1. Is an adult ≥18 years of age at the Screening visit.\n- 10. Is able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to local and institutional guidelines before the first study-specific procedure.\n- 2. Has a diagnosis of dilated cardiomyopathy (DCM) due to probable disease-causing variants of myosin heavy chain 7(MYH7), titin (TTN), or other identified genetic DCM variants, or with familial DCM.\n- 3. Has New York Heart Association (NYHA) Class II-IV at Screening with stable symptoms for ≥1 month.\n- 4. Has chronic DCM, defined as not due to acute or possibly reversible conditions (e.g., hyper/hypothyroidism, infectious cause, tachyarrhythmia, iron overload), according to the Investigator.\n- 5. Has DCM not attributed to substance abuse, amyloidosis, sarcoidosis, or any other secondary form of cardiomyopathy per the Investigator.\n- 6. Has sinus rhythm, stable atrial or ventricular pacing or paroxysmal atrial fibrillation that is adequately rate-controlled when in the arrhythmia, to allow assessments by TTE.\n- 7. Can perform an upright cardiopulmonary exercise testing (CPET) with a peak oxygen consumption (pVO2) of 80% or less of predicted for a healthy individual and RER of ≥1.05 on the Screening CPET, as confirmed by the CPET Core Laboratory.\n- 8. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. All participants, if sexually active, must use 1 of the highly effective birth control methods listed in the protocol from the Screening visit through 3 months after the last dose of IMP."}

Exclusion criteria

  • {"criterion_text":"- 1. Has heart failure with reduced ejection (HFrEF) caused primarily by ischemic heart disease, chronic valvulopathy, or another condition, as determined by the Investigator.\n- 25. Thyroid-stimulating hormone >1.5 × ULN at Screening.\n- 26. Serum creatine kinase >3 × ULN at Screening.\n- 10. History of malignancy of any type within 5 years prior to Screening, except for in situ cervical cancer, non-melanomatous skin cancers, ductal carcinoma in situ, and nonmetastatic prostate cancer, which resolved one year prior to screening.\n- 27. Positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody (anti-HCV) plus HCV-RNA. Participants who are anti-HCV positive but HCV-RNA negative (secondary to treatment or natural viral clearance) are eligible with at least a 1-year period since documented date of RNA polymerase chain reaction negative confirmation following conclusion of treatment.\n- 28. Has hypersensitivity to danicamtiv or any of the components of the danicamtiv formulation.\n- 29. Has life expectancy <6 months.\n- 3. Had coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) within prior 90 days.\n- 30. Is pregnant or breastfeeding.\n- 31. Is employed by or is a first-degree relative of someone employed by the Sponsor, the Investigator, or his/her staff or family.\n- 4. Recent (<90 days) hospitalization for heart failure (HF) or use of intravenous (IV) diuretic.\n- 18. Has planned cardiac resynchronization therapy (CRT) or major surgery planned in the next 6 months.\n- 6. Known aortic stenosis of moderate or greater severity, at the discretion of the Investigator.\n- 7. Presence of disqualifying cardiac rhythms that might interfere with reliable echocardiographic measurements of LV function, as determined by the Investigator including: (a) inadequately rate-controlled atrial fibrillation, (b) ectopic beats (atrial, junctional or ventricular) of sufficient frequency (e.g. > 10% of total beats) that the participant's cardiac rhythm is irregular potentially interfering with reliable echocardiographic measurements of LV function.\n- 11. Severe renal insufficiency (defined at the time of Screening as current estimated glomerular filtration rate [eGFR] <15 mL/min/1.73m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n- 8. Unstable or untreated severe ventricular arrythmia (eg, ventricular tachycardia or ventricular fibrillation).\n- 9. Has active infection indicated clinically as determined by the Investigator. In the case of SARS-CoV-2 (COVID-19) infection within 4 weeks prior to and during Screening, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the participant at a higher risk if receiving investigational treatment. The methods to assess SARS-CoV-2 (COVID-19) infection include polymerase chain reaction (PCR), antigen test and serology tests.\n- 5. Other recent (<90 days) cardiovascular event (e.g., cerebrovascular accident).\n- 12. History or evidence of any other clinically significant disorder, condition, or disease (including substance abuse) that, in the opinion of the Investigator or Sponsor, would pose a risk to participant safety or interfere with the study evaluation, procedures, completion, or lead to premature withdrawal from the study.\n- 13. Dependent on continuous oxygen supplementation, severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease that may impact CPET performance.\n- 14. Significant hematologic, orthopedic, neuromuscular, or rheumatologic conditions limiting exercise capacity.\n- 15. History of heart transplantation or anticipated heart transplantation in the next 6 months.\n- 19. Has a ventricular assist device or anticipated ventricular assist device placement planned in the next 6 months.\n- 16. Any condition deemed by the Investigator to pose an unacceptable risk for CPET or interfere with study assessments.\n- 17. Receives chronic IV inotropic therapy.\n- 2. Recent (<90 days) acute coronary syndrome or hemodynamically significant epicardial coronary disease, at the discretion of the Investigator.\n- 20. Participated in a clinical trial in which the participant received any investigational drug (or is currently using an investigational device) within 30 days prior to Screening, or less than 5 times the respective elimination half-life (whichever is longer).\n- 21. Serum potassium <3.5 or >5.5 mEq/L at the Screening Visit.\n- 22. Any persistent (2 or more) out-of-range safety laboratory parameters (including chemistry, hematology), considered by the Investigator and Medical Monitor to be clinically significant.\n- 23. Hemoglobin <10g/L at Screening, confirmed on repeat testing if initial result is borderline or deemed not clinically significant by the Investigator.\n- 24. Has active liver disease, defined as any known current infectious, neoplastic, or metabolic, pathology of the liver; unexplained elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN); or total bilirubin (TBL) >2 × ULN at Screening."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Change from Baseline (Day 1) to Week 26 in left atrial function index (LAFI) in Cohort 1.\n- Change from Baseline to Week 26 in peak oxygen consumption (pVO2) in Cohort 1.","definition_or_measurement_approach":"LAFI: measured by transthoracic echocardiogram (TTE) from Baseline (Day 1) to Week 26 in Cohort 1 as described in the trial main objective.\npVO2: measured by upright cardiopulmonary exercise testing (CPET) (peak oxygen consumption) from Baseline to Week 26 in Cohort 1, with CPET results confirmed by the CPET Core Laboratory."}

Recruitment

Digital Remote Recruitment
True, recruitment materials include website packages/website content and online participant materials (country-specific website material indicated in K2 recruitment documents).
Planned Sample Size
92
Recruitment Window Months
19
Consent Approach
Written informed consent is required from each participant according to local and institutional guidelines prior to any study-specific procedure (inclusion criterion: 'provide written informed consent according to local and institutional guidelines before the first study-specific procedure'). Participants are adults (≥18), so consent is provided by the participant. Multiple language ICFs and subject information documents are provided (examples include English, French, Italian, Polish, Swedish, Spanish, Dutch and country-specific versions); additional ICFs such as Pregnancy ICF, Genetic ICF and Privacy ICF are listed in the submitted documents.

Methods

  • Country-specific recruitment arrangements documents (K1_Recruitment arrangements) submitted for each participating country (examples: Italy, Netherlands, Hungary, France, Poland, Belgium, Sweden, Spain, Denmark).
  • Participant flyers (K2_Recruitment material_Flyer / ParticipantFlyer) for patient-facing print distribution (available in multiple country-specific versions).
  • Website/online recruitment materials (K2_Recruitment material_Website Package / Website content / Participant Website) for digital outreach and information.
  • GP letter (document: Other subject information material_GP Letter_Kardigan) identified as part of subject-facing materials.

Geography

Total Number Of Sites
36
Total Number Of Participants
222

Italy

Earliest CTIS Part Ii Submission Date
20-01-2026
Latest Decision Or Authorization Date
02-02-2026
Processing Time Days
13
Number Of Sites
6
Number Of Participants
36

Sites

Site Name
ASST Grande Ospedale Metropolitano Niguarda
Department Name
Cardiology 2
Principal Investigator Name
Enrico Ammirati
Principal Investigator Email
enrico.ammirati@ospedaleniguarda.it
Contact Person Name
Enrico Ammirati
Site Name
Azienda Universitaria Ospedaliera Consorziale Policlinico Bari
Department Name
University Cardiology Unit, Interdisciplinary Department of Medicine
Principal Investigator Name
Andrea Igoren Guaricci
Principal Investigator Email
andreaigoren.guaricci@uniba.it
Contact Person Name
Andrea Igoren Guaricci
Contact Person Email
andreaigoren.guaricci@uniba.it
Site Name
Azienda Ospedaliero Universitaria Careggi
Department Name
Experimental and Clinical Medicine
Principal Investigator Name
Iacopo Olivotto
Principal Investigator Email
iacopo.olivotto@unifi.it
Contact Person Name
Iacopo Olivotto
Contact Person Email
iacopo.olivotto@unifi.it
Site Name
Humanitas Mirasole S.p.A.
Department Name
Department of Cardiovascular Medicine
Principal Investigator Name
Cristina Panico
Principal Investigator Email
cristina.panico@hunimed.eu
Contact Person Name
Cristina Panico
Contact Person Email
cristina.panico@hunimed.eu
Site Name
Centro Cardiologico Monzino S.p.A.
Department Name
Heart Failure and Clinical Cardiology and Rehabilitation Department
Principal Investigator Name
Piergiuseppe Agostoni
Contact Person Name
Piergiuseppe Agostoni
Site Name
Azienda Sanitaria Universitaria Giuliano Isontina
Department Name
Cardiothoracovascular
Principal Investigator Name
Marco Merlo
Principal Investigator Email
marco.merlo@asugi.sanita.fvg.it
Contact Person Name
Marco Merlo

Netherlands

Earliest CTIS Part Ii Submission Date
21-01-2026
Latest Decision Or Authorization Date
30-04-2026
Processing Time Days
99
Number Of Sites
3
Number Of Participants
19

Sites

Site Name
Amsterdam UMC Stichting
Department Name
cardiology
Principal Investigator Name
Ahmad Amin
Principal Investigator Email
a.s.amin@amsterdamumc.nl
Contact Person Name
Ahmad Amin
Contact Person Email
a.s.amin@amsterdamumc.nl
Site Name
Academisch Ziekenhuis Maastricht
Department Name
Cardiology
Principal Investigator Name
Stephane Heymans
Principal Investigator Email
s.heymans@maastrichtuniversity.nl
Contact Person Name
Stephane Heymans
Site Name
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department Name
Department of Cardiology
Principal Investigator Name
Michelle Michels
Principal Investigator Email
m.michels@erasmusmc.nl
Contact Person Name
Michelle Michels
Contact Person Email
m.michels@erasmusmc.nl

Hungary

Earliest CTIS Part Ii Submission Date
17-11-2025
Latest Decision Or Authorization Date
29-04-2026
Processing Time Days
163
Number Of Sites
2
Number Of Participants
10

Sites

Site Name
Semmelweis University
Department Name
Városmajori Szív és Érgyógyászati Klinika
Principal Investigator Name
Béla Merkely
Principal Investigator Email
merkely.study@gmail.com
Contact Person Name
Béla Merkely
Contact Person Email
merkely.study@gmail.com
Site Name
University Of Szeged
Department Name
Belgyógyászati Klinika, Kardiológiai Centrum
Principal Investigator Name
Róbert Sepp
Principal Investigator Email
sepprobert@med.u-szeged.hu
Contact Person Name
Róbert Sepp
Contact Person Email
sepprobert@med.u-szeged.hu

France

Earliest CTIS Part Ii Submission Date
05-12-2025
Latest Decision Or Authorization Date
13-05-2026
Processing Time Days
159
Number Of Sites
2
Number Of Participants
29

Sites

Site Name
Hopitaux Universitaires Pitie Salpetriere
Department Name
Service de Cardiologie
Principal Investigator Name
Philippe Charron
Principal Investigator Email
philippe.charron@aphp.fr
Contact Person Name
Philippe Charron
Contact Person Email
philippe.charron@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
INSERM CIC1418
Principal Investigator Name
Karim Wahbi
Principal Investigator Email
karim.wahbi@aphp.fr
Contact Person Name
Karim Wahbi
Contact Person Email
karim.wahbi@aphp.fr

Poland

Earliest CTIS Part Ii Submission Date
16-12-2025
Latest Decision Or Authorization Date
28-04-2026
Processing Time Days
133
Number Of Sites
4
Number Of Participants
15

Sites

Site Name
4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
Department Name
Klinika Kardiologii
Principal Investigator Name
Bartosz Krakowiak
Principal Investigator Email
szpital@4wsk.pl
Contact Person Name
Bartosz Krakowiak
Contact Person Email
szpital@4wsk.pl
Site Name
Krakowski Szpital Specjalistyczny Im. Sw. Jana Pawla II
Department Name
Oddział Kliniczny Chorób Serca i Naczyń
Principal Investigator Name
Paweł Rubiś
Principal Investigator Email
pawelrub@poczta.onet.pl
Contact Person Name
Paweł Rubiś
Contact Person Email
pawelrub@poczta.onet.pl
Site Name
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W Lodzi
Department Name
Klinika Kardiologii
Principal Investigator Name
Jarosław Drożdż
Principal Investigator Email
jaroslaw.drozdz@umed.lodz.pl
Contact Person Name
Jarosław Drożdż
Contact Person Email
jaroslaw.drozdz@umed.lodz.pl
Site Name
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
Department Name
Klinika Niewydolności Serca i Transplantologii i Mechanicznego Wspomagania Serca
Principal Investigator Name
Przemyslaw Leszek
Principal Investigator Email
pleszek@ikard.pl
Contact Person Name
Przemyslaw Leszek
Contact Person Email
pleszek@ikard.pl

Belgium

Earliest CTIS Part Ii Submission Date
19-01-2026
Latest Decision Or Authorization Date
28-04-2026
Processing Time Days
99
Number Of Sites
5
Number Of Participants
33

Sites

Site Name
Azorg
Department Name
Cardiology
Principal Investigator Name
Marc Vanderheyden
Principal Investigator Email
marc.vanderheyden@azorg.be
Contact Person Name
Marc Vanderheyden
Contact Person Email
marc.vanderheyden@azorg.be
Site Name
UZ Leuven
Department Name
Cardiology
Principal Investigator Name
Tomas Robyns
Principal Investigator Email
tomas.robyns@uzleuven.be
Contact Person Name
Tomas Robyns
Contact Person Email
tomas.robyns@uzleuven.be
Site Name
Hopital Erasme
Department Name
Cardiology
Principal Investigator Name
Antoine Bondue
Principal Investigator Email
antoine.bondue@hubruxelles.be
Contact Person Name
Antoine Bondue
Contact Person Email
antoine.bondue@hubruxelles.be
Site Name
Universitair Ziekenhuis Antwerpen
Department Name
Cardiology
Principal Investigator Name
Emeline Van Craenenbroeck
Principal Investigator Email
emeline.vancraenenbroeck@uantwerpen.be
Contact Person Name
Emeline Van Craenenbroeck
Site Name
Jessa Ziekenhuis
Department Name
Cardiology
Principal Investigator Name
Pieter Koopman
Principal Investigator Email
Pieter.Koopman@jessazh.be
Contact Person Name
Pieter Koopman
Contact Person Email
Pieter.Koopman@jessazh.be

Sweden

Earliest CTIS Part Ii Submission Date
02-01-2026
Latest Decision Or Authorization Date
04-05-2026
Processing Time Days
122
Number Of Sites
2
Number Of Participants
18

Sites

Site Name
Soedersjukhuset AB
Department Name
VO Kardiologi
Principal Investigator Name
Gianluigi Savarese
Principal Investigator Email
gianluigi.savarese@ki.se
Contact Person Name
Gianluigi Savarese
Contact Person Email
gianluigi.savarese@ki.se
Site Name
Danderyds Sjukhus AB
Department Name
VO Hjärt-Fysiologi
Principal Investigator Name
Krister Lindmark
Principal Investigator Email
krister.lindmark@regionstockholm.se
Contact Person Name
Krister Lindmark

Spain

Earliest CTIS Part Ii Submission Date
13-01-2026
Latest Decision Or Authorization Date
29-04-2026
Processing Time Days
106
Number Of Sites
9
Number Of Participants
48

Sites

Site Name
Area Sanitaria Da Coruna E Cee
Department Name
Cardiology
Principal Investigator Name
Roberto Barriales Villa
Principal Investigator Email
Roberto.Barriales.Villa@sergas.es
Contact Person Name
Roberto Barriales Villa
Site Name
University Hospital Virgen Del Rocio S.L.
Department Name
Cardiology
Principal Investigator Name
Maria Luisa Peña Peña
Contact Person Name
Maria Luisa Peña Peña
Site Name
Hospital Universitario Puerta De Hierro De Majadahonda
Department Name
Cardiology
Principal Investigator Name
Pablo Garcia Pavia
Contact Person Name
Pablo Garcia Pavia
Site Name
Hospital Son Llatzer
Department Name
Cardiology
Principal Investigator Name
Jorge Álvarez Rubio
Principal Investigator Email
jalvarezr@hsll.es
Contact Person Name
Jorge Álvarez Rubio
Contact Person Email
jalvarezr@hsll.es
Site Name
Hospital Universitari Vall D Hebron
Department Name
Cardiology
Principal Investigator Name
Javier Limeres Freire
Principal Investigator Email
javier.limeres@vallhebron.cat
Contact Person Name
Javier Limeres Freire
Contact Person Email
javier.limeres@vallhebron.cat
Site Name
Bellvitge University Hospital
Department Name
Cardiology
Principal Investigator Name
Fernando de Frutos Seminario
Principal Investigator Email
fdefrutos@bellvitgehospital.cat
Contact Person Name
Fernando de Frutos Seminario
Site Name
University Clinical Hospital Virgen De La Arrixaca
Department Name
Cardiology
Principal Investigator Name
Juan Ramon Gimeno Blanes
Principal Investigator Email
jgimeno@secardiologia.es
Contact Person Name
Juan Ramon Gimeno Blanes
Contact Person Email
jgimeno@secardiologia.es
Site Name
Hospital Universitario Virgen De La Victoria
Department Name
Cardiology
Principal Investigator Name
Ainhoa Robles Mezcua
Principal Investigator Email
ainhoa.mezcua@gmail.com
Contact Person Name
Ainhoa Robles Mezcua
Contact Person Email
ainhoa.mezcua@gmail.com
Site Name
Hospital (additional Spanish site listed)
Department Name
Cardiology

Denmark

Earliest CTIS Part Ii Submission Date
08-01-2026
Latest Decision Or Authorization Date
24-04-2026
Processing Time Days
106
Number Of Sites
3
Number Of Participants
14

Sites

Site Name
Region Midtjylland
Department Name
Department of Cardiology
Principal Investigator Name
Torsten Rasmussen
Principal Investigator Email
torasm@rm.dk
Contact Person Name
Torsten Rasmussen
Contact Person Email
torasm@rm.dk
Site Name
Rigshospitalet
Department Name
Department of Cardiology
Principal Investigator Name
Anna Axelsson Raja
Principal Investigator Email
anna.axelsson.raja@regionh.dk
Contact Person Name
Anna Axelsson Raja
Contact Person Email
anna.axelsson.raja@regionh.dk
Site Name
Odense University Hospital
Department Name
Department of Cardiology
Principal Investigator Name
Thomas Hey
Principal Investigator Email
thomas.morris.hey@rsyd.dk
Contact Person Name
Thomas Hey
Contact Person Email
thomas.morris.hey@rsyd.dk

Sponsor

Primary sponsor

Full Name
Kardigan Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Contract research organisations

Name
Medpace Finland Oy
Name
Clinchoice Inc.
Name
Veranex Inc.
Name
Medidata Solutions Inc.
Name
Suvoda LLC

Third parties

  • {"country":"Finland","full_name":"Medpace Finland Oy","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Baim Institute For Clinical Research Inc.","duties_or_roles":"ARO; Adjudication; ECG testing","organisation_type":"Educational Institution"}
  • {"country":"United States","full_name":"The Brigham And Women’s Hospital Inc.","duties_or_roles":"Imaging - ECHO","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"United States","full_name":"Prolaio Inc.","duties_or_roles":"ePROs; Wearable Devices","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Mural Health Technologies Inc.","duties_or_roles":"Patient Travel and Reimbursement Support","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Massachusetts General Hospital","duties_or_roles":"Imaging - CPET","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"United States","full_name":"Veranex Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Thermo Fisher Scientific Inc.","duties_or_roles":"","organisation_type":"Industry"}
  • {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Suvoda LLC","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Clinchoice Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Alturas Analytics Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Ambry Genetics Corp.","duties_or_roles":"","organisation_type":"Laboratory/Research/Testing facility"}

Investigational products

Investigational Product Name
Danicamtiv
Active Substance
DANICAMTIV
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
ORAL

Related trials

Other published trials that may interest you.